Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Executive summary

Conclusions

3 evidence topics · 22 sources

Summary: efficacy and safety evidence for barzolvolimab
  • Phase 3 efficacy: EMBARQ-CSU1 (963 participants randomized) and EMBARQ-CSU2 (976 participants randomized) compared barzolvolimab 150 mg every 4 weeks (after a 300 mg loading dose) and 300 mg every 8 weeks (after a 450 mg loading dose) with placebo. Both trials met the primary endpoint of mean change from baseline in UAS7 at Week 12, and the company states that all key secondary endpoints were met. The LS mean change in UAS7 at Week 12 was -20.2 (150 mg) and -20.5 (300 mg) compared with -10.7 (placebo) in EMBARQ-CSU1, and -20.2 and -19.7 compared with -11.4 in EMBARQ-CSU2 (p<.00001 for each dose). Complete response (UAS7=0) at Week 12 was reported in 42.4% and 42.1% compared with 9.3% in EMBARQ-CSU1, and in 45.7% and 44.0% compared with 12.6% in EMBARQ-CSU2.
  • Omalizumab-refractory participants: UAS7=0 at Week 12 was reported in 55.3% (150 mg, N=52) and 44.3% (300 mg, N=52) compared with 9.3% (placebo, N=55) in EMBARQ-CSU1, and in 41.7% (N=44) and 46.4% (N=42) compared with 15.1% (N=43) in EMBARQ-CSU2.
  • Durability: in the phase 2 trial, the company reports UAS7=0 at Week 52 in 71% of participants treated with 150 mg every 4 weeks and 52% treated with 300 mg every 8 weeks, and at Week 76, seven months after the final dose, in 41% and 35%. Phase 3 treatment continues to 52 weeks.
  • Phase 3 safety through the 24-week placebo-controlled period, pooled across both trials (placebo N=645, 150 mg N=648, 300 mg N=641): at least 1 adverse event in 52.7%, 75.6%, and 76.8%; hair color changes in 4.5%, 45.1%, and 51.5%; skin hypopigmentation in 2.5%, 11.0%, and 10.0%; neutropenia in 0.6%, 9.1%, and 11.7%; dysgeusia in 1.4%, 6.8%, and 9.8%; and serious adverse events in 2.3%, 0.9%, and 2.2%. Infection rates were 23.9%, 24.4%, and 23.6%, and the company states that neutropenia was not associated with increased incidence of infections. Anaphylaxis adjudicated as probable was reported in 0 participants with placebo, 2 with 150 mg, and, in the 300 mg group, “1 (occurred after placebo dose)”.
  • Reversibility: the company reports that in phase 2, neutrophil counts returned to baseline after treatment and hair color changes and skin hypopigmentation were reversible after treatment was discontinued. In a phase 2 pigmentation analysis over 76 weeks, 91% of evaluable participants with hair color changes reported resolution by the end of study participation, and 68% of evaluable participants with skin hypopigmentation reported resolution by data cutoff.
Summary: regulatory timing and evidence gaps
  • Regulatory timing: barzolvolimab is in phase 3 development and has no FDA-approved prescribing information. The phase 3 trials were initiated in July 2024, completed enrollment in February 2026, and reported topline results on September 22, 2026 (data cutoff September 9, 2026). The company anticipates additional 24-week phase 3 results in February 2027 and a BLA submission to the FDA in 2027. The ClinicalTrials.gov records give an estimated study completion of 2027-06 for both phase 3 trials, and the phase 3b long-term extension has an estimated primary completion of 2028-09. No FDA expedited program designation for CSU was found. A U.S. composition of matter patent has an estimated expiry in 2034.
  • Publication status: the phase 3 results are available only as topline results in a company press release and investor presentation, and no peer-reviewed publication of them was found; the company plans to present the data at an upcoming medical meeting. Values are not reported for the key secondary endpoints of ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants. The Week 24 UAS7=0 results are presented by the company, and the current ClinicalTrials.gov records list no Week 24 UAS7 outcome.
  • Safety reporting: phase 3 adverse events are reported pooled across both trials through Week 24, with no trial-level counts and no counts of discontinuation for adverse events.
  • Health-related quality of life: baseline DLQI is reported for both phase 3 trials, and no DLQI or other health-related quality of life result after baseline is reported.
  • Immunogenicity: antidrug antibody data come from the phase 1b study with intravenous dosing, in which 57% (20/35) of participants were ADA positive in the publication, without apparent impact on exposure; a poster at the November 2022 data cutoff reported treatment-emergent ADA in 51%. No antidrug antibody results from the phase 2 or phase 3 CSU trials were found.
  • Pharmacokinetics and dosing: no subcutaneous bioavailability, time to peak concentration, or half-life values were found, and no dose regimen proposed for licensure was found. The phase 3 trials test both regimens; retreatment in the phase 3b extension uses a 300 mg loading dose followed by 150 mg every 4 weeks.
  • Price: no published price and no budget impact model for barzolvolimab were found.
  • Population: the phase 3 trials enrolled adults and excluded participants with a history of anaphylaxis; no evidence in pediatric participants was found.
Summary: barzolvolimab and current therapies
  • Approved advanced therapies: omalizumab is indicated for CSU in adults and adolescents 12 years of age and older at 150 mg or 300 mg by subcutaneous injection every 4 weeks, is initiated in a healthcare setting, and carries a boxed warning for anaphylaxis. Dupilumab is indicated for CSU in patients aged 2 years and older, with an adult dosage of 600 mg followed by 300 mg every 2 weeks. Remibrutinib was approved by the FDA in September 2025 as an oral treatment for adults, at 25 mg twice daily. Barzolvolimab is studied at 150 mg every 4 weeks or 300 mg every 8 weeks by subcutaneous injection from 1 mL pre-filled syringes, which the manufacturer states allows potential self-administration at home.
  • Guideline position: the 2026 international guideline recommends add-on omalizumab and suggests add-on dupilumab or remibrutinib for CSU unresponsive to high doses of second-generation H1-antihistamines, states that remibrutinib can be considered especially in patients who do not respond to both high-dose antihistamines and omalizumab, acknowledges restrictions on all three because of their high cost, and notes that treatments under development aim, among other approaches, to reduce mast cell numbers. A network meta-analysis conducted to update the AAAAI/ACAAI joint task force chronic urticaria guideline found with high certainty that standard-dose omalizumab (300 mg every 4 weeks) and remibrutinib are among the most effective, and stated that the safety profile of remibrutinib is less certain and that the impact of dupilumab on quality of life is uncertain.
  • Pivotal trial results, each against its own placebo group: UAS7=0 at Week 12 was reported in 36% with omalizumab 300 mg and 9% with placebo in CSU Trial 1, and in 31.1% with remibrutinib and 10.5% with placebo in REMIX-1 and 27.9% and 6.5% in REMIX-2. With dupilumab, UAS7 = 0 at Week 24 was reported in 32.4% compared with 13.2% in CUPID Study A and 30.1% compared with 17.3% in Study C, and CUPID Study B, in participants with inadequate response to or intolerance of anti-IgE treatment, did not meet its primary endpoint. The barzolvolimab phase 3 trials included omalizumab-refractory participants (results above). No head-to-head trial of barzolvolimab with these therapies was found, and the company states that cross-study comparisons are limited by differences in trial design, statistical methods, patient populations, and dosing schedules.
  • Prices: remibrutinib is listed at $4,521 per 30-day supply (as of January 7, 2026), dupilumab at $4,193.03 per 4-week supply (as of January 1, 2026), and omalizumab at a Genentech-stated list price of approximately $30,000 - $60,000 annually. Omalizumab biosimilar competition became available in 2026, and a negotiated Medicare Maximum Fair Price for Xolair is scheduled to take effect January 1, 2028.
  • Manufacturer positioning: the company describes barzolvolimab as positioned “as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice.”